Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study

Cancer Gene Therapy

Volumn 21, Issue 3, 2014, Pages 91-94

  Benedict, W F ^a   Fisher, M ^a   Zhang, X Q ^a   Yang, Z ^a   Munsell, M F ^a   Dinney, C N P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoviral mediated interferon treatment; Bladder cancer; Phase l study; Urine cytokeratin 18 levels

Indexed keywords

ALPHA INTERFERON; CYTOKERATIN 18; CYTOKERATIN 18 M30; CYTOKERATIN 18 M65; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CASPASE; CHOLIC ACID DERIVATIVE; DISACCHARIDE; M30 CYTOKERATIN-18 PEPTIDE, HUMAN; M65 ANTIGEN, HUMAN; PEPTIDE FRAGMENT; SYN3 COMPOUND;

ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER REGRESSION; CELL DEATH; CONTROLLED STUDY; CYSTECTOMY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; URINALYSIS; URINE LEVEL; APOPTOSIS; CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; URINARY BLADDER NEOPLASMS; URINE;

MYCOBACTERIUM BOVIS BCG;

APOPTOSIS; CASPASES; CELL DEATH; CHOLIC ACIDS; DISACCHARIDES; HUMANS; INTERFERON-ALPHA; KERATIN-18; PEPTIDE FRAGMENTS; URINARY BLADDER NEOPLASMS;

EID: 84897087491     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.1     Document Type: Article

References (11)

1. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A et al. Phase I trial of intravesical recombinant adenovirus-mediated interferon-a2b formulated in syn3 for BCG failures in non-muscle-invasive bladder cancer. J Urol 2013; 190: 850-856.
2. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L et al. Intravesical Ad-IFN alpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004; 10: 525-532.
3. Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained:implications for clinical investigation. Cancer Gene Therapy 2006; 13: 125-130.
4. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict WF, Dinney CP et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004; 64: 8973-8979.
5. Zhang X-Q, Yang Z, Dong L, Papageorgiou A, McConkey D, Benedict WF. Adenoviral-mediated interferon a overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Therapy 2007; 14: 241-250.
6. Zhang X-Q, Dong L, Chapman E, Benedict WF. Conditioned medium from Ad-IFNalpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Therapy 2008; 12: 817-822.
7. Zhang X-Q, Yang Z, Benedict WF. Direct gene transfer of adenoviral-mediated interferon a into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related related cytotoxicity. Cancer Gene Therapy 2011; 18: 260-264.
8. Zhibo Y, Zhang XQ, Dinney CNP, Benedict WF. Direct cytotoxicity produced by adenoviral-mediated interferon a infection in interferon resistant cancer cells involves ER stress and caspase 4 activation. Cancer Gene Therapy 2011; 18: 609-616.
9. Fisher MB, Zhang X-Q, McConkey DJ, Benedict WF. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker. Cancer Gene Therapy 2009; 16: 567-572.
10. Linder S. Cytokeratin markers come of age. Tumor Biol 2007; 28: 189-195.
11. de Hass EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJH, Lancashire LJ et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug -sensitive tumor, testicular cancer. Neoplasia 2008; 10: 1041-1048.